metformin has been researched along with Cancer of Nasopharynx in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "With antitumor activity, metformin can have low toxicity when used in combination with some common chemotherapy drugs." | 5.72 | Effects of Cisplatin Combined with Metformin on Proliferation and Apoptosis of Nasopharyngeal Carcinoma Cells. ( Duan, X; Mei, Y; Shi, L; Wang, B, 2022) |
| "Metformin has been shown to be useful in reducing insulin resistance by restoring sensitivity." | 5.40 | Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. ( Jiang, CC; Jiang, ZW; Li, HH; Liu, H; Sun, XJ; Zhang, P, 2014) |
| "Metformin users had a lower risk of death due to nasopharyngeal cancer (adjusted HR = 0." | 1.91 | The Association between Metformin and the Cancer-Specific Mortality Rate in Nasopharyngeal Cancer Patients: Real-World Evidence. ( Hsu, CY; Hsu, Y; Kao, YS, 2023) |
| "With antitumor activity, metformin can have low toxicity when used in combination with some common chemotherapy drugs." | 1.72 | Effects of Cisplatin Combined with Metformin on Proliferation and Apoptosis of Nasopharyngeal Carcinoma Cells. ( Duan, X; Mei, Y; Shi, L; Wang, B, 2022) |
| "Metformin has anticancer effects, but whether it can reduce the risk of nasopharyngeal cancer (NPC) is not known." | 1.48 | Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus. ( Tseng, CH, 2018) |
| "Metformin has been shown to be useful in reducing insulin resistance by restoring sensitivity." | 1.40 | Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. ( Jiang, CC; Jiang, ZW; Li, HH; Liu, H; Sun, XJ; Zhang, P, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, L | 1 |
| Mei, Y | 1 |
| Duan, X | 1 |
| Wang, B | 1 |
| Hsu, Y | 1 |
| Hsu, CY | 1 |
| Kao, YS | 1 |
| Sun, Y | 1 |
| Chen, X | 2 |
| Zhou, Y | 1 |
| Qiu, S | 1 |
| Wu, Y | 1 |
| Xie, M | 1 |
| Zhu, G | 1 |
| Liang, S | 1 |
| Li, H | 2 |
| Zhou, D | 1 |
| Ju, Z | 1 |
| Wang, F | 1 |
| Han, F | 1 |
| Wang, Z | 2 |
| Wang, R | 1 |
| Chen, Z | 1 |
| Zeng, Z | 1 |
| Zhu, S | 1 |
| Zeng, Y | 1 |
| Lin, Q | 1 |
| Luo, L | 1 |
| Hong, X | 1 |
| Tseng, CH | 1 |
| Hahn, SS | 1 |
| Tang, Q | 1 |
| Zheng, F | 1 |
| Zhao, S | 1 |
| Wu, J | 1 |
| Chen, J | 1 |
| Sun, XJ | 1 |
| Zhang, P | 1 |
| Li, HH | 1 |
| Jiang, ZW | 1 |
| Jiang, CC | 1 |
| Liu, H | 1 |
| Yu, Y | 1 |
| Zuo, Y | 1 |
| Li, S | 1 |
| Yang, D | 1 |
| Hu, S | 1 |
| Xiang, M | 1 |
| Xu, Z | 1 |
| Yu, Z | 1 |
| Zhao, L | 1 |
| Wen, ZH | 1 |
| Jia, CH | 1 |
| Li, M | 1 |
| Luo, SQ | 1 |
| Bai, XC | 1 |
9 other studies available for metformin and Cancer of Nasopharynx
| Article | Year |
|---|---|
Effects of Cisplatin Combined with Metformin on Proliferation and Apoptosis of Nasopharyngeal Carcinoma Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Humans; Metformin; Nasopharyngeal Carcin | 2022 |
The Association between Metformin and the Cancer-Specific Mortality Rate in Nasopharyngeal Cancer Patients: Real-World Evidence.
Topics: Aged; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nasopharyngeal Carcinoma; N | 2023 |
Metformin reverses the drug resistance of cisplatin in irradiated CNE-1 human nasopharyngeal carcinoma cells through PECAM-1 mediated MRPs down-regulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug R | 2020 |
Effects of different combined regimens of cisplatin, metformin, and quercetin on nasopharyngeal carcinoma cells and subcutaneous xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Heterografts; | 2021 |
Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus.
Topics: Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; | 2018 |
Repression of integrin-linked kinase by antidiabetes drugs through cross-talk of PPARγ- and AMPKα-dependent signaling: role of AP-2α and Sp1.
Topics: AMP-Activated Protein Kinases; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene | 2014 |
Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Carcinoma; Cell Li | 2014 |
Metformin inhibits the growth of nasopharyngeal carcinoma cells and sensitizes the cells to radiation via inhibition of the DNA damage repair pathway.
Topics: Apoptosis; Carcinoma; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA | 2014 |
Metformin induces G1 cell cycle arrest and inhibits cell proliferation in nasopharyngeal carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Carcinom | 2011 |